Striverdi Respimat (Olodaterol HCl) Patent Expiration, LOE Window & CMS Spending
Striverdi Respimat (Olodaterol HCl) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2027-01-19, 0 AB generics, $5.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N203108 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2027-01-19 |
| Last Listed Patent or Exclusivity Date | 2027-01-19 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $5.5M |
| 2024 Medicare Part D Spend | $4.9M |
| 2024 Medicaid Spend | $550K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.